Render Target: SSR
Render Timestamp: 2024-11-14T22:34:06.900Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-04-05 20:22:17.621
Product last modified at: 2024-06-27T13:36:07.282Z
1% for the planet logo
PDP - Template Name: Blocking Peptide
PDP - Template ID: *******6db2f4c

GSK-3β Blocking Peptide #1073

Pricing & Additional Information

To learn more about our Blocking Peptides, including pricing or custom products, please submit a product inquiry request.

Submit Blocking Peptide Inquiry

    Product Information

    Product Usage Information

    Use as a blocking reagent to evaluate the specificity of antibody reactivity in dot blot protocols.

    Storage

    Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. 1% DMSO. Store at –20°C.

    Product Description

    This peptide is used specifically to block GSK-3β (27C10) Rabbit mAb #9315 reactivity.

    Quality Control

    The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks GSK-3beta (27C10) Rabbit mAb #9315 by dot blot.

    Background

    Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.